![Yelak Biru: Is myeloma science and clinical progress fast or slow?](https://oncodaily.com/pub/uploads/2024/07/GRQbzheaUAAwOyy-e1719909226126.jpg)
Photo from Yelak Biru/X
Jul 3, 2024, 06:28
Yelak Biru: Is myeloma science and clinical progress fast or slow?
Yelak Biru, President and CEO at the International Myeloma Foundation, shared on X:
“Is myeloma science and clinical progress fast or slow? Or just intentional?
- 2003/2006 – The 1st Bortezomib and Lenalidomide received FDA approval (L1 and L2)
- 2015 – SWOG S0777 published RVd as SOC for NDMM (L3)
- 2024 – 4 drug combo may become SOC for NDMM (non-frail) (L4)”
Source: Yelak Biru/X